www.hivandhepatitis.com

Back HCV Treatment

Pharmasset Selects Investigational HCV Polymerase Inhibitor PSI-879 for Preclinical Development

Details
Category: HCV Treatment
Published on Friday, 09 October 2009 14:01
Written by Pharmasset
  • Print

Pharmasset, Inc. recently announced that it has chosen its experimental hepatitis C virus (HCV) polymerase inhibitor PSI-352879 (or PSI-879 for short) -- a purine nucleotide analog -- as a candidate for further preclinical development. PSI-879, as well as the company's other investigational nucleoside/nucleotide analogs, may potentially be suitable for use in combination regimens with other directly-targeted oral anti-HCV drugs now in the pipeline.

Read more:

Subcategories

Copyright © 2026 www.hivandhepatitis.com. All Rights Reserved. Designed by JoomlArt.com. Joomla! is Free Software released under the GNU General Public License.

Bread and Roses Web DesignWeb Design and Development by Bread and Roses Web Design